Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

Table 3 MiniHCVD-inotuzumab ozogamicin regimen for acute lymphoblastic leukemia

Treatment type	Schedule	Drug	Dose
Intensive phase	Cycles 1, 3, 5, 7	Cyclophosphamide	150 mg/m² every 12 h, days 1–3
		Dexamethasone	20 mg/d, days 1–4 and 11–14
		Vincristine	2 mg flat dose, days 1 and 8
	Cycles 2, 4, 6, 8	Methotrexate	250 mg/m², day 1
	Cycles 2, 4, 6, 8	Cytarabine	0.5 g/m² every 12 h, days 2 and 3
	Cycle 1	Inotuzumab	1.3 mg/m², day 3
	Cycles 2, 3, 4	Inotuzumab	1.0 mg/m², day 3
	Cycles 1, 2, 3, 4	Rituximab*	375 mg/m², days 1 and 8
Maintenance therapy	Months 1–12	Vincristine	2 mg/d every month
	Months 1–12	Prednisone	50 mg/d for 5 days every month
	Months 1–36	6-Mercaptopurine	50 mg PO twice daily
	Months 1–36	Methotrexate	10 mg/m² PO weekly
Central nervous system prophylaxis	Cycles 1, 3	IT MTX-AraC	MTX 12 mg on day 2, AraC 100 mg day 8
Central nervous system prophylaxis	Cycles 2, 4	IT AraC-MTX	AraC 100 mg on day 5, MTX 12 mg day 8
Supportive care	Cycles 1–8	Pegfilgrastim	6 mg subcutaneously day 4
Supportive care	Cycles 1–5	Ursodiol	300 mg, 3 times daily

Note: *Rituximab was administered in patients with CD20 expression of 20% or higher. It was noted that the schedules of rituximab and CNS prophylaxis have been modified in the latest publications and variations exist since the trials are still ongoing [108, 109]. For details on correct doses and schedules, those from original publications should be followed
Inotuzumab denotes inotuzumab ozogamicin; IT intrathecal, MTX methotrexate, AraC cytarabine

ISSN: 1756-8722